Sector Expert: David Martin
David Martin serves as the managing director and head of equity research at Bloom Burton & Co. Before joining Bloom Burton, Martin most recently served as vice president, corporate development and investor relations at a fast-growing medical device company. Earlier in his career, he led the healthcare equity research team at an independent Canadian investment bank, and he has also worked for a global clinical diagnostics company. Martin received a Ph.D. in biochemistry from the University of Western Ontario for his research into transgenic suppression of tumors. He also holds a master's degree in business administration from the Richard Ivey School of Business.
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based in Canada, where resource stocks have absorbed so much investment capital that many healthcare names have remained hidden and undervalued. In this interview with The Life Sciences Report, Martin highlights a group of companies with superior growth prospects and room to run.